Davide Verotta Mechanistic and Non-mechanistic Drug Dynamics Modeling
|
Janet Wade Miscellaneous regulatory information
|
Roberto Gomeni1, Jean M. Joulia1,2, Frédéric Pinguet 2, Marc Ychou3 and Françoise Bressolle1,2 Circadian Population Pharmacokinetics of 5-Fluorouracil (5-FU) in Patients with Metastatic Colorectal Cancer
|
Gordon Graham1, Leon Aarons1 and Suneel Gupta2 A Bayesian Analysis of Categorical and Count Pharmacodynamic Data
|
Rik C. Schoemaker, Joop M.A. van Gerven & Adam F. Cohen Estimating potency for the Emax-model without attaining maximal effects
|
Silvy Laporte, Pascal Girard, Patrick Mismetti, Sylvie Chabaud What Is The Relevance Of Estimating Inter-Study Variability In Population Pharmacokinetic Meta-Analysis ?
|
Nick Holford Clinical Pharmacology = Disease Progress + Drug Action. The role of clinical trial modelling, simulation and analysis using the population PKPD approach.
|
Jean-Michel Gries, Pharm.D, Ph.D.(1), Davide Verotta, Ph.D.(2), Lewis B. Sheiner, M.D.(3) Estimation of individual pharmacokinetic parameters in presence of possible non-compliance
|
Rashmi R Shah Limitations of Population Approaches in Regulatory Assessment of New Chemical Entities
|
ML McFadyen(1), SF Marshall (2), PA Milligan(2), DJ Nichols(2) MO Karlsson(3) Clinical versus statistical significance in covariate selection
|
S. F. Marshall(1), P. A. Milligan(1), D. J. Nichols(1) and M. O. Karlsson(2) Do we require the population approach to dose adjust in renal impairment? : A case study with dofetilide
|
Kazimierz H. Kozlowski Semi-Populational Model For Analysis Of Infusable Immunoglobulin-G Pharmacokinetics In VLBW Infants
|
SB Duffull (1), JJ Deely (2). NHG Holford (3). Comparison Of A Semiparametric Method With Nonmem For Population Analysis Of Simulated Data
|
Dave Lunn and Jon Wakefield The analysis of ordinal pharmacodynamic data: applicationto allergy score.
|
Mats O Karlsson and E Niclas Jonsson An Automated Stepwise Covariate Model Building Procedure Within NONMEM
|
Silvy Laporte, Pascal Girard, Patrick Mismetti, Sylvie Chabaud What Is The Relevance Of Estimating Inter-Study Variability In Population Pharmacokinetic Meta-Analysis?
|
J.-L. Steimer, B. Fotteler, R. Gieschke, H.Wiltshire, N. Buss Mixed-effects modeling and simulation of the Dose-AUC relationship of saquinavir in healthy subjects and HIV-positive patients (II)
|
Misba Beerahee, PhD(1) and Mark Sale, MD(2) An integrated population PK-PD model characterising the time course of exposure and clinical endpoints (biochemical, physiological and haemodynamics) for 546C88, a nitric oxide synthase inhibitor, in patients with septic shock.
|